September 15 World Lymphoma Awareness Day – Know Lymphoma, Why It Matters
In this article
Know Lymphoma: Why It Matters, Key Symptoms & Treatment Pathways
A clear, patient-friendly guide for awareness, earlier diagnosis, and better outcomes.
⚠️ Why Is This Important?
September 15 marks World Lymphoma Awareness Day worldwide. Lymphoma is one of the most common blood cancers. Despite its frequency, public awareness of lymph node function and the early signs of lymphoma remains low. Earlier recognition and timely treatment are critical determinants of survival.
🧬 What Is Lymphoma?
Lymphoma is a group of cancers that arise from lymph nodes or other lymphoid tissues. Two major categories:
- Classical Hodgkin Lymphoma (cHL): Characterized by Hodgkin/Reed–Sternberg cells; typically CD30-positive, CD45/CD3-negative immunophenotype.
- Non-Hodgkin Lymphoma (NHL): Numerous subtypes of B-cell, T-cell, or NK-cell origin; biology, natural history, and treatment differ from cHL.
🔎 Most Common Symptoms
- Painless lymph node swelling (lymphadenopathy): Neck, axilla, groin, supraclavicular regions; in cHL, mediastinal mass is frequent.
- “B” symptoms: Fever > 38 °C, profuse night sweats, ≥10% unintentional weight loss in 6 months. Present in ~40% of cHL; more common in aggressive NHL.
- Itching (pruritus): Occurs in ~10–15% of cHL; can be widespread and severe.
- Extranodal disease: GI tract, skin, testis, bone, CNS, and other non-node organs may be involved.
Less common / special signs
- Alcohol-induced pain: Uncommon but relatively specific for cHL; pain in nodes/pressure areas after alcohol.
- Hepatosplenomegaly, and lab changes (anemia, leukocytosis, eosinophilia, thrombocytosis, hypercalcemia).
- Oncologic emergencies (esp. aggressive NHL): Spinal cord compression, airway compromise, tumor lysis syndrome.
🧪 How Is the Diagnosis Made?
- Gold standard: Excisional/incisional lymph node biopsy or multiple core needle biopsies. Fine-needle aspiration is often insufficient for precise subtyping.
- Pathology & immunophenotyping: Morphology plus CD markers and molecular/cytogenetic analyses.
- Staging: PET-CT/CT and blood tests guide treatment and prognosis.
🩺 Treatment Overview & Decision Pathway
Management depends on subtype (Hodgkin vs. Non-Hodgkin), stage, prognostic factors, age, and comorbidities. Typical steps:
- Diagnosis & Staging: Pathology, immunophenotyping, and PET-CT staging to define disease extent.
- Risk Stratification: Tools such as the International Prognostic Index (IPI) or Ann Arbor staging.
- First-line Therapy Selection:
- Classical Hodgkin Lymphoma: Standard is ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine); escalated BEACOPP in selected advanced-stage cases.
- Aggressive B-cell NHL (e.g., DLBCL): R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) is standard.
- Indolent NHL: Observation or rituximab-based regimens; “watch-and-wait” is appropriate in low-burden disease.
- Response Assessment: Early and end-of-treatment PET-CT to guide continuation, intensification, or change.
- Consolidation / Autologous Stem Cell Transplant: Consider in refractory or high-risk disease.
- Immunotherapy & Targeted Agents:
- Anti-CD20 antibodies (Rituximab, Obinutuzumab) are foundational for B-cell NHL.
- Checkpoint inhibitors (Nivolumab, Pembrolizumab) especially for relapsed/refractory Hodgkin lymphoma.
- CAR-T cells: For aggressive, treatment-resistant B-cell lymphomas.
- Supportive Care: Infection prophylaxis, growth factors, nutrition, and psychosocial support.
- Long-term Follow-up: Surveillance for second cancers, cardiotoxicity, and late effects.
📣 Awareness Saves Lives
Public surveys show low awareness of lymph node function and lymphoma symptoms. Campaigns such as “Know Your Nodes” promote early presentation and faster diagnosis. Earlier-stage lymphoma is more often curable and associated with longer survival.
- If you notice a painless, persistent swelling, seek medical attention promptly.
- If B-symptoms (fever–sweats–weight loss) occur, ask for a clinical evaluation.
✅ Quick Self-Check
- Have you had a painless lymph node swelling for 2–4 weeks?
- Have you lost ≥10% body weight in the last 6 months?
- Do you experience fever > 38 °C or profuse night sweats?
- Any unexplained fatigue or itching?
📊 Approximate 5-Year Survival by Subtype
Outcomes have improved substantially with combination chemotherapy, anti-CD20 antibodies, PET-adapted strategies, immunotherapies, and—where appropriate—transplant/CAR-T. (Individual results vary by stage, age/comorbidities, and treatment response.)
- In early-stage cHL, 5-year survival can reach 90–95%+.
- In DLBCL, outcomes are higher in low-risk IPI; lower in refractory/high risk.
- Follicular disease often has long survival with a chronic course.
- For Mantle cell, targeted/immunotherapies and transplant/CAR-T can improve results.
🌟 Final Message
Early diagnosis saves lives. If you notice suspicious signs, don’t delay—consult an expert physician. Use September 15 as a reminder to invite everyone around you to “know their lymph nodes.”
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.